Citations

Showing 10 of 108094 citations.

Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
Ono, Masafumi , Serruys, Patrick W. , Garg, Scot , Kawashima, Hideyuki , Gao, Chao , Hara, Hironori , Lunardi, Mattia , O’Leary, Neil , Mack, Michael J. , Holmes, David R. , Morice, Marie‐Claude, Thuijs, Daniel J.F.M. , Mohr, Friedrich W., Davierwala, Piroze , Spertus, John A. , Onuma, Yoshinobu , Investigators, for the SYNTAX Extended Survival, Piek, Jan J , Mack, Michael J , Holmes, David R , Thuijs, Daniel J F M , Spertus, John A , Cohen, David Jonathan , Onuma, Yoshinobu , Serruys, Patrick W , Garg, Scot , Wang, Rutao , Wykrzykowska, Joanna J. , Kappetein, A. Pieter , Noack, Thilo , Investigators, for the SYNTAX Extended Survival

Mayo Clinic

Circulation | October 24, 2022 | Volume: 146 | Issue: 17 | Pages: 1268-1280

10.1161/circulationaha.121.057021 | PMID 35862109 Get It

Background: Clinical and anatomical characteristics are often considered key factors in deciding between percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) in patients with complex coronary artery disease (CAD) such as left-main CAD or 3-vessel disease. However, little is known about the interaction between self-reported preprocedural physical/mental health and clinical outcomes after revascularization. Methods: This subgroup analysis of the SYNTAXES trial (SYNTAX Extended Survival), which is the extended follow-up of the randomized SYNTAX trial (Synergy Between PCI With Taxus and Cardiac Surgery) comparing PCI with CABG in patients with left-main CAD or 3-vessel disease, stratified patients by terciles of Physical (PCS) or Mental Component Summary (MCS) scores derived from the preprocedural 36-Item Short Form Health Survey, with higher PCS and MCS scores representing better physical and mental health, respectively. The primary end point was all-cause death at 10 years. Results: A total of 1656 patients with preprocedural 36-Item Short Form Health Survey data were included in the present study. Both higher PCS and MCS were independently associated with lower 10-year mortality (10-point increase in PCS adjusted hazard ratio, 0.84 [95% CI, 0.73–0.97]; P =0.021; in MCS adjusted hazard ratio, 0.85 [95% CI, 0.76–0.95]; P =0.005). A significant survival benefit with CABG over PCI was observed in the highest PCS (>45.5) and MCS (>52.3) terciles with significant treatment-by-subgroup interactions (PCS P interaction =0.033, MCS P interaction =0.015). In patients with both high PCS (>45.5) and MCS (>52.3), 10-year mortality was significantly higher with PCI compared with CABG (30.5% versus 12.2%; hazard ratio, 2.87 [95% CI, 1.55–5.30]; P =0.001), whereas among those with low PCS (≤45.5) or low MCS (≤52.3), there were no significant differences in 10-year mortality between PCI and CABG, resulting in a significant treatment-by-subgroup interaction ( P interaction =0.002). Conclusions: Among patients with left-main CAD or 3-vessel disease, patient-reported preprocedural physical and mental health status was strongly associated with long-term mortality and modified the relative treatment effects of PCI versus CABG. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI. Assessment of self-reported physical and mental health is important when selecting the optimal revascularization strategy. Registration: URL: https://www.clinicaltrials.gov ; SYNTAXES Unique identifier: NCT03417050. URL: https://www.clinicaltrials.gov ; SYNTAX Unique identifier: NCT00114972.
Incidence and risk of attention-deficit/hyperactivity disorder and learning disability by adulthood after traumatic brain injury in childhood: a population-based birth cohort study
Esterov, Dmitry , Zielinski, Martin D. , Weaver, Amy L. , Mara, Kristin C. , Ferrara, Michael J. , Immermann, Joseph M. , Moir, Christopher R. , Brown, Allen W. , Esterov, Dmitry , Moir, Christopher, Mara, Kristin C

Mayo Clinic

Child Neuropsychology | October 24, 2022 | Volume: 29 | Issue: 5 | Pages: 808-824

10.1080/09297049.2022.2136645 | PMID 36278854 Get It

Explainable Preoperative Automated Machine Learning Prediction Model for Cardiac Surgery-Associated Acute Kidney Injury
Pattharanitima, Pattharawin , Kattah, Andrea G. , Mao, Michael A. , Keddis, Mira T. , Dillon, John, Kaewput, Wisit , Tangpanithandee, Supawit , Krisanapan, Pajaree , Cheungpasitporn, Wisit , Pattharanitima, Pattharawin , Mao, Michael A , Keddis, Mira , Dillon, John J, Kaewput, Wisit , Tangpanithandee, Supawit , Krisanapan, Pajaree , Cheungpasitporn, Wisit , Thongprayoon, Charat , Qureshi, Fawad

Mayo Clinic

Journal of Clinical Medicine | October 24, 2022 | Volume: 11 | Issue: 21 | Pages: 6264

10.3390/jcm11216264 | PMID 36362493 Get It

Background: We aimed to develop and validate an automated machine learning (autoML) prediction model for cardiac surgery-associated acute kidney injury (CSA-AKI). Methods: Using 69 preoperative variables, we developed several models to predict post-operative AKI in adult patients undergoing cardiac surgery. Models included autoML and non-autoML types, including decision tree (DT), random forest (RF), extreme gradient boosting (XGBoost), and artificial neural network (ANN), as well as a logistic regression prediction model. We then compared model performance using area under the receiver operating characteristic curve (AUROC) and assessed model calibration using Brier score on the independent testing dataset. Results: The incidence of CSA-AKI was 36%. Stacked ensemble autoML had the highest predictive performance among autoML models, and was chosen for comparison with other non-autoML and multivariable logistic regression models. The autoML had the highest AUROC (0.79), followed by RF (0.78), XGBoost (0.77), multivariable logistic regression (0.77), ANN (0.75), and DT (0.64). The autoML had comparable AUROC with RF and outperformed the other models. The autoML was well-calibrated. The Brier score for autoML, RF, DT, XGBoost, ANN, and multivariable logistic regression was 0.18, 0.18, 0.21, 0.19, 0.19, and 0.18, respectively. We applied SHAP and LIME algorithms to our autoML prediction model to extract an explanation of the variables that drive patient-specific predictions of CSA-AKI. Conclusion: We were able to present a preoperative autoML prediction model for CSA-AKI that provided high predictive performance that was comparable to RF and superior to other ML and multivariable logistic regression models. The novel approaches of the proposed explainable preoperative autoML prediction model for CSA-AKI may guide clinicians in advancing individualized medicine plans for patients under cardiac surgery.
Editorial Comment
Frendl, Daniel

Mayo Clinic

Journal of Urology | October 24, 2022 | Volume: 209 | Issue: 1 | Pages: 168-169

10.1097/ju.0000000000002993.03 | PMID 36278264 Get It

4 Pulmonary vein anatomical variants and incidence of atrial fibrillation
Gallen, R, Apolinario, M, Sorajja, D, Gallen, Rory, Apolinario, Michael

Mayo Clinic

Oral abstract presentations 1 | October 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: A4.1-A4

10.1136/heartjnl-2022-ics.4 Get It

Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]
Seoud, Mudieddine, Ladjeroud, Amel, Jaafar, Hassan, Mokhtar, Mohsen, Alkhayyat, Shadi , Dawood, Shaheenah , Arık, Zafer , Azim, Hamdy A., Özyılkan, Özgür

Mayo Clinic

Current Women s Health Reviews | October 24, 2022 | Volume: 20 | Issue: 1 | Pages: No page available

10.2174/1573404819666221021091708 Get It

Abstract: Worldwide, ovarian cancer (OC) is one of the leading causes of cancer-related death among women. Despite the recent progress in the treatment of advanced OC, oncologists in many parts of the world still face several difficulties and constraints in their daily management of their patients. In addition to the shortage of resources and expertise, non-adherence to the up to date international guidelines has been identified as a major obstacle towards the improvement of treatment outcomes in the majority of developing countries, including the Middle East and North African (MENA) countries. A multidisciplinary gynecological oncology panel from the MENA region met virtually in December 2020 to discuss the challenges and hurdles faced by the community oncologists in the management of advanced OC. This manuscript reviews the key molecular and clinical studies that shaped the current international guidelines and suggests several modifications to make them more adaptable to the health status of developing countries of this region
Cabozantinib Following Immunotherapy in Patients with Advanced Hepatocellular Carcinoma
Storandt, Michael H. , Gile, Jennifer , Palmer, Mathias Earl, Ahn, Daniel H. , Bekaii‐Saab, Tanios , Jin, Zhaohui , Tran, Nguyen H. , Mahipal, Amit , Gile, Jennifer Jane , Palmer, Mathias E, Zemla, Tyler J, Jin, Zhaohui , Tran, Nguyen , Mahipal, Amit , Bekaii-Saab, Tanios S , Zemla, Tyler

Mayo Clinic

Cancers | October 23, 2022 | Volume: 14 | Issue: 21 | Pages: 5173

10.3390/cancers14215173 | PMID 36358592 Get It

(1) Background: Cabozantinib, a multikinase inhibitor, is approved by the Food and Drug Administration (FDA) for the treatment of advanced hepatocellular carcinoma (HCC) following progression on sorafenib. Recently, atezolizumab plus bevacizumab has been approved in the first line setting for advanced HCC and has become the new standard of care. Whether cabozantinib improves outcomes following progression on immunotherapy remains unknown. We describe the clinical outcomes following treatment with immunotherapy in patients with advanced HCC who received cabozantinib. (2) Methods: We conducted a multicentric, retrospective analysis of patients with advanced HCC diagnosed between 2010–2021 at Mayo Clinic in Minnesota, Arizona, and Florida who received cabozantinib. Median overall survival and progression free survival analyses were performed using the Kaplan–Meier method. Adverse events were determined using Common Terminology Criteria for Adverse Events (CTCAE). (3). Results: We identified 26 patients with advanced HCC who received cabozantinib following progression on immunotherapy. Median progression free survival on cabozantinib therapy was 2.1 months (95% CI: 1.3–3.9) and median overall survival from time of cabozantinib initiation was 7.7 months (95% CI: 5.3–14.9). (4) Conclusion: The optimal sequencing of therapy for patients with advanced HCC following progression on immunotherapy remains unknown. Our study demonstrates that patients may benefit from treatment with cabozantinib following progression on immunotherapy.
Accurate and efficient measurement of channelized Hotelling observer‐based low‐contrast detectability on the ACR CT accreditation phantom
Fan, Mingdong, Thayib, Theodore, McCollough, C, Yu, Lifeng , McCollough, Cynthia, Yu, Lifeng

Mayo Clinic

Medical Physics | October 23, 2022 | Volume: 50 | Issue: 2 | Pages: 737-749

10.1002/mp.16068 | PMID 36273393 Get It

AbstractBackgroundCurrent CT quality control (QC) for low‐contrast detectability relies on visual inspection and measurement of contrast‐to‐noise ratio (CNR). However, CNR numbers become unreliable when it comes to nonlinear methods, such as iterative reconstruction (IR) and deep‐learning‐based techniques. Image quality metrics using channelized Hotelling observer (CHO) have been validated to be well correlated with human observer performance on phantom‐based and patient‐based tasks, but it has not been widely used in routine CT QC mainly because the CHO calculation typically requires a large number of repeated scans in order to provide accurate and precise estimate of index of detectability (d′).PurposeThe main goal of this work is to optimize channel filters and other CHO parameters and accurately estimate the low‐contrast detectability with minimum number of repeated scans for the widely used American College of Radiology (ACR) CT accreditation phantom so that it can become practically feasible for routine CT QC tests.MethodsTo provide a converged d′ value, an ACR phantom was repeatedly scanned 100 times at three dose levels (24, 12, and 6 mGy). Images were reconstructed with two kernels (FBP Br44 and IR Br44‐3). d′ as a function of number of repeated scans was determined for different number of background regions of interest (ROIs), different number of low‐contrast objects, different number of slices per each object, and different channel filter options. A reference d′ was established using the optimized CHO setting, and the bias of d′ was quantified using the d′ calculated from all 100 repeated scans. The variation of d′ at each condition was estimated using a resampling method combining random subsampling among 100 repeated scans and bootstrapping of the ensembles of signal and background ROIs.ResultsOptimized parameters in CHO calculation were determined: two background ROIs per object, four objects per low‐contrast object size, nine non‐overlapping slices per object, and a 4‐channel Gabor filter. The bias and uncertainty were estimated at different numbers of repeated scans using these parameters. When only one single scan was used in the CHO calculation, the bias of d′ was below 6.2% and the uncertainty 15.6‐19.6% for the 6, 5, and 4 mm objects, while with three repeated scans the bias was below 2.0% and uncertainty 8.7‐10.9% for the three object sizes.ConclusionWith optimized parameter settings in CHO, efficient and accurate measurement of low‐contrast detectability on the commonly used ACR phantom becomes feasible, which could potentially lead to adoption of CHO‐based low‐contrast evaluation in routine QC tests.
mTORC2 contributes to systemic autoimmunity
Qi, Haiyu, Li, Meilu , Li, Yanfeng , Zhu, Xingxing , Amin, Shreyasee , Alexander, Mariam P., Diadhiou, Catherine M.M. , Zeng, Hu , Alexander, Mariam , Zeng, Hu , Zhu, Xingxing , Zhou, Xian , Davidson, Anne

Mayo Clinic

Immunology | October 23, 2022 | Volume: 168 | Issue: 3 | Pages: 554-568

10.1111/imm.13594 | PMID 36273262 Get It

AbstractThe development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia and increased follicular helper T (Tfh)‐cell differentiation. However, the cellular and molecular mechanisms underlying these immunological perturbations remain incompletely understood. Here, we show that the mechanistic target of rapamycin complex 2 (mTORC2) promotes Tfh differentiation and disrupts Treg homeostasis. Inactivation of mTORC2 in total T cells, but not in Tregs, greatly ameliorated the immunopathology in a systemic autoimmunity mouse model. This was associated with reduced Tfh differentiation, B‐cell activation, and reduced T‐cell glucose metabolism. Finally, we show that type I IFN can synergize with TCR ligation to activate mTORC2 in T cells, which partially contributes to T‐cell lymphopenia. These data indicate that mTORC2 may act as downstream of type I IFN, TCR and costimulatory receptor ICOS, to promote glucose metabolism, Tfh differentiation, and T‐cell lymphopenia, but not to suppress Treg function in systemic autoimmunity. Our results suggest that mTORC2 might be a rational target for systemic autoimmunity treatment.
Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn’s Disease
Chugh, Rishika , Neto, Manuel B. Braga , Fredrick, Thomas , Terdiman, Jonathan P., El‐Nachef, Najwa , Loftus, Edward V. , Mahadevan, Uma , Kane, Sunanda V. , Braga Neto, Manuel B , Fredrick, Thomas W , Loftus, Edward V , Mahadevan, Uma , Kane, S , Ramos, Guilherme Piovezani

Mayo Clinic

Journal of Crohn's and Colitis | October 22, 2022 | Volume: 17 | Issue: 4 | Pages: 504-512

10.1093/ecco-jcc/jjac157 | PMID 36272109 Get It

Abstract Background Upadacitinib is a selective Janus kinase inhibitor approved for the management of ulcerative colitis and is under evaluation for the management of Crohn’s disease [CD] in Phase 3 clinical trials. Aims Our goal was to describe our real-world experience with upadacitinib in CD. Methods This is a two-centre retrospective cohort study of adult patients with moderate to severe CD on upadacitinib. The primary outcome was clinical response and remission as determined by stool frequency and abdominal pain scores. Secondary endpoints included endoscopic response and remission as determined by change in Simple Endoscopic Score for CD. Outcomes were assessed at 3 months after starting upadacitinib and at the patient’s most recent follow-up. We further evaluated adverse events and dose-related response. Results A total of 45 CD patients received upadacitinib and were included in the safety analysis. Thirty-six patients received upadacitinib for CD, whereas nine received it for inflammatory arthritis [n = 8] or pyoderma [n = 1]. Thirty-three patients received upadacitinib for 3 months or longer and were included in the efficacy analysis. At the 3-month follow-up, 21 patients achieved clinical response [63.6%] and nine achieved clinical remission [27.2%]. At time of last follow-up, 23 patients had clinical response [69.7%], ten achieved clinical remission [30.3%] and four [28.6%] achieved endoscopic remission. Adverse events occurred in 12 patients [26.7%]. Two patients had a serious adverse event [4.5%] without associated mortality. Conclusion In this real-world cohort of highly refractory CD patients, upadacitinib was effective in inducing remission and had an acceptable safety profile.